Nonadherence to medical therapy is frequently encountered in patients with inflammatory bowel disease (IBD).
Dr Mirjam Severs and colleagues identified predictors for future (non)adherence in IBD.
The researchers conducted a multicenter prospective cohort study with adult patients with Crohn's disease (CD) and ulcerative colitis (UC).
Data were collected by means of 3-monthly questionnaires on the course of disease and healthcare utilization.
Medication adherence was assessed using a visual analogue scale, ranging from 0% to 100%.
Levels less than 80% were considered to indicate nonadherence.
The research team used the Brief Illness Perception Questionnaire to identify illness perceptions.
The team used a logistic regression analysis to identify patient- and disease-related factors predictive of nonadherence 3 months after the assessment of predictors.
In total, the team included 1558 patients with CD and 1054 patients with UC, and followed for 2.5 years.
On average, 12% of patients with CD and 13% of patients with UC using IBD-specific medication were nonadherent.
The researchers observed nonadherence most frequently in patients using mesalazine (CD), budesonide (UC) and rectally administrated therapy.
The team noted that a higher perceived treatment control and understanding of the disease were associated with adherence to medical therapy.
Independent predictors of future nonadherence were age at diagnosis, nonadherence, a current flare, and feelings of anxiety/depression, together with an area under the receiver-operating-characteristics curve of 0.74.
Dr Severs' team concludes, "Lower age at diagnosis, flares, feelings of anxiety or depression, and nonadherence are associated with future nonadherence in patients with IBD."
"Altering illness perceptions could be an approach to improve adherence behavior."